Single-Dose PanChol Shows Strong Safety and Immune Response in Phase 1 trial
A new study published in the journal of The Lancet Infectious Diseases showed that over a 100,000-fold dosage range, a single oral dose of PanChol produced 100% vibriocidal seroconversion and…